203 related articles for article (PubMed ID: 30141083)
1. Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum.
Jiao P; Zhang J; Dong Y; Wei D; Ren Y
Appl Microbiol Biotechnol; 2018 Nov; 102(22):9585-9594. PubMed ID: 30141083
[TBL] [Abstract][Full Text] [Related]
2. Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells.
Lv X; Zhang J; Xu R; Dong Y; Sun A; Shen Y; Wei D
Appl Microbiol Biotechnol; 2016 Jul; 100(14):6403-6413. PubMed ID: 27063011
[TBL] [Abstract][Full Text] [Related]
3. Directing ricin-based immunotoxins with targeting affibodies and KDEL signal peptide to cancer cells effectively induces apoptosis and tumor suppression.
Park SG; Kim H; Jun H; Choi SY; Kim E; Kang S
J Nanobiotechnology; 2022 Aug; 20(1):387. PubMed ID: 35999603
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of KDEL-terminated ricin toxins correlates with distribution of the KDEL receptor in the Golgi.
Tagge E; Chandler J; Tang BL; Hong W; Willingham MC; Frankel A
J Histochem Cytochem; 1996 Feb; 44(2):159-65. PubMed ID: 8609372
[TBL] [Abstract][Full Text] [Related]
5. Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Xiang Y; Li Q; Huang D; Tang X; Wang L; Shi Y; Zhang W; Yang T; Xiao C; Wang J
Exp Biol Med (Maywood); 2015 Feb; 240(2):160-8. PubMed ID: 25125500
[TBL] [Abstract][Full Text] [Related]
6. Expression of ricin A chain and ricin A chain-KDEL in Escherichia coli.
Zhan J; Chen Y; Wang K; Zheng S
Protein Expr Purif; 2004 Apr; 34(2):197-201. PubMed ID: 15003251
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
8. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of a recombinant human beta defensin 2 fusion protein targeting the epidermal growth factor receptor: in vitro study.
Zhang M; Qiu Z; Li Y; Yang Y; Zhang Q; Xiang Q; Su Z; Huang Y
Appl Microbiol Biotechnol; 2013 May; 97(9):3913-23. PubMed ID: 22903275
[TBL] [Abstract][Full Text] [Related]
10. Modification of ricin A chain, by addition of endoplasmic reticulum (KDEL) or Golgi (YQRL) retention sequences, enhances its cytotoxicity and translocation.
Zhan J; Stayton P; Press OW
Cancer Immunol Immunother; 1998 Mar; 46(1):55-60. PubMed ID: 9520293
[TBL] [Abstract][Full Text] [Related]
11. Generation of a potent chimeric toxin by replacement of domain III of Pseudomonas exotoxin with ricin A chain KDEL.
Pitcher C; Roberts L; Fawell S; Zdanovsky AG; FitzGerald DJ; Lord JM
Bioconjug Chem; 1995; 6(5):624-9. PubMed ID: 8974463
[TBL] [Abstract][Full Text] [Related]
12. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
13. A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses.
Naemi AA; Salmanian AH; Noormohammadi Z; Amani J
Eur J Pharmacol; 2023 Sep; 955():175894. PubMed ID: 37429519
[TBL] [Abstract][Full Text] [Related]
14. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
[TBL] [Abstract][Full Text] [Related]
15. Cell-penetrating and endoplasmic reticulum-locating TAT-IL-24-KDEL fusion protein induces tumor apoptosis.
Zhang J; Sun A; Xu R; Tao X; Dong Y; Lv X; Wei D
J Cell Physiol; 2016 Jan; 231(1):84-93. PubMed ID: 26031207
[TBL] [Abstract][Full Text] [Related]
16. Genetically encoded immunophotosensitizer 4D5scFv-miniSOG is a highly selective agent for targeted photokilling of tumor cells in vitro.
Mironova KE; Proshkina GM; Ryabova AV; Stremovskiy OA; Lukyanov SA; Petrov RV; Deyev SM
Theranostics; 2013; 3(11):831-40. PubMed ID: 24312153
[TBL] [Abstract][Full Text] [Related]
17. Addition of an endoplasmic reticulum retrieval sequence to ricin A chain significantly increases its cytotoxicity to mammalian cells.
Wales R; Roberts LM; Lord JM
J Biol Chem; 1993 Nov; 268(32):23986-90. PubMed ID: 8226941
[TBL] [Abstract][Full Text] [Related]
18. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF
J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254
[TBL] [Abstract][Full Text] [Related]
19. HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis.
Sokolova E; Guryev E; Yudintsev A; Vodeneev V; Deyev S; Balalaeva I
Oncotarget; 2017 Mar; 8(13):22048-22058. PubMed ID: 28423549
[TBL] [Abstract][Full Text] [Related]
20. Ricin A chain reaches the endoplasmic reticulum after endocytosis.
Liu Q; Zhan J; Chen X; Zheng S
Biochem Biophys Res Commun; 2006 May; 343(3):857-63. PubMed ID: 16564502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
